Lifecore Biomedical, Inc. Common Stock (LFCR) Stock
Key stats
- Market cap
- $242.60M
- Price / Earnings ratio
- -3.3x
- EPS (TTM)
- -$1.95
- Volume
- Loading
- 52-week high
- $8.98
- 52-week low
- $3.63
Source: third-party data provider, as of November 13, 2026
Compare with LFCR
Recent news

Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
LFCR

LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
LFCR

Lifecore Biomedical Q2 Earnings Call Highlights
Lifecore Biomedical Q2 Earnings Call Highlights
LFCR

3 Penny Stocks To Buy According To Analysts, Targets Up To %170
3 Penny Stocks To Buy According To Analysts, Targets Up To %170
LFCR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 62.57
- MACD 12/26/9
- 0.14
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.06
- SMA 50
- $5.72
- Price above SMA 50
- EMA 50
- $5.92
- Price above EMA 50
- SMA 200
- $5.43
- Price above SMA 200
- EMA 200
- $5.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
Lifecore Biomedical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lifecore Biomedical, Inc. - LFCR
LFCR

LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
LFCR Stock Alert: Halper Sadeh LLC is Investigating Whether Lifecore Biomedical, Inc. is Obtaining a Fair Price for its Shareholders
LFCR

Lifecore Biomedical Q2 Earnings Call Highlights
Lifecore Biomedical Q2 Earnings Call Highlights
LFCR

3 Penny Stocks To Buy According To Analysts, Targets Up To %170
3 Penny Stocks To Buy According To Analysts, Targets Up To %170
LFCR

3 Penny Stocks To Buy According To Analysts, Targets Up To 170%
3 Penny Stocks To Buy According To Analysts, Targets Up To 170%
LFCR
News tone: automated (AI) classification of the article's content, not a price prediction.
About Lifecore Biomedical, Inc. Common Stock
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Josephs | President, CEO & Director | 1966 |
| Mr. Ryan D. Lake CPA | Executive VP & CFO | 1977 |
| Mr. Thomas D. Salus | Chief Legal & Administration Officer and Corporate Secretary | 1970 |
| Mr. Thomas Guldager | Senior Vice President of Operations | — |
| Mr. Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer | — |
| Ms. Jackie Q. Klecker | Executive Vice President of Quality & Development Services | — |
| Mr. Mark DaFonseca | Chief Commercial Officer | — |
| Mr. Parker K. Javid | Vice President | 1969 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 62.57
- MACD 12/26/9
- 0.14
- EMA 9 of MACD
- 0.20
- MACD histogram
- -0.06
- SMA 50
- $5.72
- Price above SMA 50
- EMA 50
- $5.92
- Price above EMA 50
- SMA 200
- $5.43
- Price above SMA 200
- EMA 200
- $5.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- -
- Average
- -
- High
- -
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.4 | +32.0 | -4.6 | +8.2 | -16.1 | +1.6 | +49.9 | -2.0 | +0.2 |



